Connecteve, a South Korean company developing AI-powered end-to-end orthopedic solutions, has successfully closed its Series A funding round, raising approximately $10.5 million (KRW 14 billion). The round included follow-on investments from existing backers DSC Investment, Stonebridge Ventures, Schmidt, and Reventures, while new investors BSK Investment, TS Investment, IMM Investment, JB Investment, and Big Move Ventures joined, bringing the total number of participating VCs to nine.  

“This investment is a testament to Connecteve’s unique technology and future growth potential, despite the global economic slowdown and contraction in the venture capital market,” the company stated. The funding reflects high expectations for its AI-driven medical solutions—CONNEVO KOA, ALI, and Suite—set to launch this year. These solutions harness artificial intelligence to support personalized treatment planning for patients while providing orthopedic surgeons with advanced analytical tools, aiming to redefine medical care.  

Connecteve has successfully completed or is currently executing 19 government-backed projects, including the Ministry of SMEs and Startups’ Scale-up TIPS program and a scale-up initiative by Seoul National University Hospital, securing approximately $3 million (KRW 4 billion) in government funding. The company has also demonstrated its technological capabilities by publishing 18 international collaborative research papers. Through these efforts, it continues to advance AI-driven medical technology and solidify its position as a trusted player in the global healthcare market.  

Starting this year, Connecteve plans to commercialize its R&D achievements domestically and internationally and has already secured major South Korean hospitals as key customers. Notably, Bumin Hospital, which operates over 670 beds, has joined this funding round as a strategic investor (SI) and will collaborate with Connecteve on commercialization efforts.  

In January, the company successfully completed a proof-of-concept (PoC) for its AI software at a hospital under Burjeel Holdings, a leading healthcare group in Abu Dhabi. Building on this success, Connecteve is ramping up its expansion into the Middle East. At the same time, it is in the final stages of obtaining CE certification for entry into the European market, while also working on Singaporean and Japanese medical certifications to expand into Southeast Asia and Japan. The company is also coordinating the timeline for FDA approval.  

“Our goal is to develop AI-powered personalized treatment and orthopedic surgery support systems that provide real value to both patients and medical professionals,” said Connecteve CEO Doohyun Noh. “With this investment, we will accelerate R&D for global market expansion and lead the way in advancing AI and medical robotics technology.”